Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis
The recent discovery of the Janus activating kinase 2 V617F mutation in most patients with polycythemia vera (PV) and half of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF) has favored the hypothesis of a biological continuum from ET over PV to PMF. We performed gene expre...
Saved in:
Published in | Experimental hematology Vol. 40; no. 9; pp. 771 - 780.e19 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Inc
01.09.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The recent discovery of the Janus activating kinase 2 V617F mutation in most patients with polycythemia vera (PV) and half of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF) has favored the hypothesis of a biological continuum from ET over PV to PMF. We performed gene expression profiling of whole blood from control subjects (n = 21) and patients with ET (n = 19), PV (n = 41), and PMF (n = 9) using DNA microarrays. Applying an unsupervised method, principal component analysis, to search for patterns in the data, we demonstrated a separation of the four groups with biological relevant overlaps between the different entities. Moreover, the analysis separates Janus activating kinase 2-negative ET patients from Janus activating kinase 2-positive ET patients. Functional annotation analysis demonstrates that clusters of gene ontology terms related to inflammation, immune system, apoptosis, RNA metabolism, and secretory system were the most significantly deregulated terms in the three different disease groups. Our results yield further support for the hypothesis of a biological continuum originating from ET over PV to PMF. Functional analysis suggests an important implication of these gene ontology clusters in the pathogenesis of these neoplasms and in disease evolution from ET over PV to PMF. |
---|---|
AbstractList | The recent discovery of the Janus activating kinase 2 V617F mutation in most patients with polycythemia vera (PV) and half of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF) has favored the hypothesis of a biological continuum from ET over PV to PMF. We performed gene expression profiling of whole blood from control subjects (n = 21) and patients with ET (n = 19), PV (n = 41), and PMF (n = 9) using DNA microarrays. Applying an unsupervised method, principal component analysis, to search for patterns in the data, we demonstrated a separation of the four groups with biological relevant overlaps between the different entities. Moreover, the analysis separates Janus activating kinase 2-negative ET patients from Janus activating kinase 2-positive ET patients. Functional annotation analysis demonstrates that clusters of gene ontology terms related to inflammation, immune system, apoptosis, RNA metabolism, and secretory system were the most significantly deregulated terms in the three different disease groups. Our results yield further support for the hypothesis of a biological continuum originating from ET over PV to PMF. Functional analysis suggests an important implication of these gene ontology clusters in the pathogenesis of these neoplasms and in disease evolution from ET over PV to PMF. The recent discovery of the Janus activating kinase 2 V617F mutation in most patients with polycythemia vera (PV) and half of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF) has favored the hypothesis of a biological continuum from ET over PV to PMF. We performed gene expression profiling of whole blood from control subjects (n = 21) and patients with ET (n = 19), PV (n = 41), and PMF (n = 9) using DNA microarrays. Applying an unsupervised method, principal component analysis, to search for patterns in the data, we demonstrated a separation of the four groups with biological relevant overlaps between the different entities. Moreover, the analysis separates Janus activating kinase 2-negative ET patients from Janus activating kinase 2-positive ET patients. Functional annotation analysis demonstrates that clusters of gene ontology terms related to inflammation, immune system, apoptosis, RNA metabolism, and secretory system were the most significantly deregulated terms in the three different disease groups. Our results yield further support for the hypothesis of a biological continuum originating from ET over PV to PMF. Functional analysis suggests an important implication of these gene ontology clusters in the pathogenesis of these neoplasms and in disease evolution from ET over PV to PMF.The recent discovery of the Janus activating kinase 2 V617F mutation in most patients with polycythemia vera (PV) and half of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF) has favored the hypothesis of a biological continuum from ET over PV to PMF. We performed gene expression profiling of whole blood from control subjects (n = 21) and patients with ET (n = 19), PV (n = 41), and PMF (n = 9) using DNA microarrays. Applying an unsupervised method, principal component analysis, to search for patterns in the data, we demonstrated a separation of the four groups with biological relevant overlaps between the different entities. Moreover, the analysis separates Janus activating kinase 2-negative ET patients from Janus activating kinase 2-positive ET patients. Functional annotation analysis demonstrates that clusters of gene ontology terms related to inflammation, immune system, apoptosis, RNA metabolism, and secretory system were the most significantly deregulated terms in the three different disease groups. Our results yield further support for the hypothesis of a biological continuum originating from ET over PV to PMF. Functional analysis suggests an important implication of these gene ontology clusters in the pathogenesis of these neoplasms and in disease evolution from ET over PV to PMF. The recent discovery of the Janus activating kinase 2 V617F mutation in most patients with polycythemia vera (PV) and half of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF) has favored the hypothesis of a biological continuum from ET over PV to PMF. We performed gene expression profiling of whole blood from control subjects (n = 21) and patients with ET (n = 19), PV (n = 41), and PMF (n = 9) using DNA microarrays. Applying an unsupervised method, principal component analysis, to search for patterns in the data, we demonstrated a separation of the four groups with biological relevant overlaps between the different entities. Moreover, the analysis separates Janus activating kinase 2-negative ET patients from Janus activating kinase 2-positive ET patients. Functional annotation analysis demonstrates that clusters of gene ontology terms related to inflammation, immune system, apoptosis, RNA metabolism, and secretory system were the most significantly deregulated terms in the three different disease groups. Our results yield further support for the hypothesis of a biological continuum originating from ET over PV to PMF. Functional analysis suggests an important implication of these gene ontology clusters in the pathogenesis of these neoplasms and in disease evolution from ET over PV to PMF. |
Author | Hasselbalch, Hans Carl Kruse, Torben A. Skov, Vibe Riley, Caroline H. Bjerrum, Ole Weis Jensen, Morten K. Larsen, Thomas Stauffer Thomassen, Mads |
Author_xml | – sequence: 1 givenname: Vibe surname: Skov fullname: Skov, Vibe email: vibe.skov@ouh.regionsyddanmark.dk organization: Department of Clinical Genetics, Odense University Hospital, Odense, Denmark – sequence: 2 givenname: Mads surname: Thomassen fullname: Thomassen, Mads organization: Department of Clinical Genetics, Odense University Hospital, Odense, Denmark – sequence: 3 givenname: Caroline H. surname: Riley fullname: Riley, Caroline H. organization: Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark – sequence: 4 givenname: Morten K. surname: Jensen fullname: Jensen, Morten K. organization: Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark – sequence: 5 givenname: Ole Weis surname: Bjerrum fullname: Bjerrum, Ole Weis organization: Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark – sequence: 6 givenname: Torben A. surname: Kruse fullname: Kruse, Torben A. organization: Department of Clinical Genetics, Odense University Hospital, Odense, Denmark – sequence: 7 givenname: Hans Carl surname: Hasselbalch fullname: Hasselbalch, Hans Carl organization: Department of Hematology, Roskilde Hospital, University of Copenhagen, Copenhagen, Denmark – sequence: 8 givenname: Thomas Stauffer surname: Larsen fullname: Larsen, Thomas Stauffer organization: Department of Hematology, Odense University Hospital, Odense, Denmark |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22659388$$D View this record in MEDLINE/PubMed |
BookMark | eNqVUk1v1DAQtVAR3Rb-AUI-csl2nMT5QAipqqBFqsQBkLhZjnfS9ZLYwXYK-T38UWbZ0gMSqvDFGvu95_F7c8KOnHfI2HMBawGiOtut8ce0xXGdg8jXINcgxCO2Ek1dZHnRtkdsBQWIrKzzL8fsJMYdAEjZwhN2nOeVbIumWbGfl-iQk1LAGK13fAq-t4N1N_y7TVsqrTN20gM3fpyoA5e4dnpYoo18g5M1KfK0Rd5ZP_gba34jXbJunkfeBz9yEiaWpYu0pbrzZiHCaDX3txj45Ifl_oQONE-ejwsO1EcXPL3zlD3u9RDx2d1-yj6_e_vp4iq7_nD5_uL8OjNlDSnrRNvXspeI0NVdD1LXWvbQ56Kqu67rdQUIpilbWqZqjcmxqkQuSlkaWZRNccpeHnTJg28zxqRGGw0Og3bo56gEFIUsqqasCPriDjp3I24U2TTqsKg_xhKgPAAMfSEG7O8hAtQ-P7VTh_zUPj8FUlF-RHv1F83YpBMFk4K2w0PkNwcykkm3FoOKxqIzuLEBTVIbb_9XwNAk7DP9igvGnZ8DRU9GqEgc9XE_X_vxEjmAaCpJAq__LfDw-78Asirn0g |
CitedBy_id | crossref_primary_10_1016_j_leukres_2015_11_017 crossref_primary_10_1080_10428194_2016_1262032 crossref_primary_10_1111_bjh_16152 crossref_primary_10_1016_j_leukres_2013_09_001 crossref_primary_10_1038_s41598_017_02655_7 crossref_primary_10_1111_ejh_12332 crossref_primary_10_3390_cancers15174323 crossref_primary_10_1016_j_leukres_2015_09_002 crossref_primary_10_3389_fimmu_2023_1117466 crossref_primary_10_1002_ccr3_281 crossref_primary_10_1038_s41467_022_32928_3 crossref_primary_10_3109_10428194_2013_764417 crossref_primary_10_1016_S0145_2126_16_30076_5 crossref_primary_10_1080_10428194_2019_1579323 crossref_primary_10_1182_blood_2014_02_554634 crossref_primary_10_1586_17474086_2015_1045409 crossref_primary_10_1016_j_leukres_2012_07_009 crossref_primary_10_1111_ejh_12684 crossref_primary_10_1016_j_leukres_2014_07_006 crossref_primary_10_1371_journal_pone_0161570 crossref_primary_10_1371_journal_pone_0112786 crossref_primary_10_1155_2015_869242 crossref_primary_10_1371_journal_pone_0135463 crossref_primary_10_1371_journal_pone_0183620 crossref_primary_10_3390_cancers12123565 crossref_primary_10_3390_cancers12082250 crossref_primary_10_1155_2015_648090 crossref_primary_10_1111_ejh_12437 crossref_primary_10_1007_s00281_018_0700_2 crossref_primary_10_1016_j_leukres_2014_04_002 crossref_primary_10_1515_sagmb_2016_0066 crossref_primary_10_3390_ijms22020561 crossref_primary_10_1007_s11136_015_1125_1 crossref_primary_10_3390_ijms22041906 crossref_primary_10_1016_j_leukres_2016_02_004 crossref_primary_10_1155_2024_1827127 crossref_primary_10_1186_s13045_017_0425_z crossref_primary_10_1080_09537104_2024_2304173 crossref_primary_10_1371_journal_pone_0085567 crossref_primary_10_1080_17474086_2017_1284583 crossref_primary_10_1007_s12032_022_01825_6 crossref_primary_10_3109_10428194_2016_1143938 crossref_primary_10_1371_journal_pone_0270669 crossref_primary_10_1016_j_blre_2017_05_001 crossref_primary_10_1016_j_cytogfr_2013_01_004 crossref_primary_10_3390_antiox9111037 crossref_primary_10_1155_2015_102476 crossref_primary_10_1016_j_leukres_2013_07_002 crossref_primary_10_3390_cancers12071763 |
Cites_doi | 10.1080/10428190500331329 10.1200/JCO.2009.23.6075 10.1158/0008-5472.CAN-04-1910 10.1182/blood-2008-01-134114 10.1093/nar/gkn923 10.1182/blood-2008-03-143537 10.1016/j.exphem.2005.01.015 10.3324/haematol.2010.031070 10.1016/j.exphem.2007.01.053 10.3324/haematol.2009.020412 10.1111/j.1600-0609.2007.00960.x 10.1056/NEJMra063728 10.1186/gb-2001-2-8-research0032 10.1182/blood-2005-05-1889 10.1242/jcs.03053 10.1182/blood.V6.4.372.372 10.1034/j.1600-0609.2001.00359.x 10.1046/j.1365-2141.2000.02030.x 10.1182/blood-2010-08-258772 10.2174/138920208786847971 10.1182/blood-2009-03-209544 10.1158/0008-5472.CAN-10-1731 10.1200/JCO.2010.34.5298 10.1182/blood-2009-03-209262 10.1038/sj.leu.2404209 10.1200/JCO.2004.00.9316 10.1158/1078-0432.CCR-10-1092 10.1634/stemcells.2006-0351 10.1016/0268-960X(93)90024-X 10.1182/blood-2005-12-4824 10.1182/blood-2007-08-107748 10.1038/leu.2008.357 10.1517/13543784.2011.579560 10.1111/j.1365-2141.1979.tb03739.x 10.1038/leu.2008.112 10.3109/10428194.2011.597905 10.1634/stemcells.2004-0131 10.1038/leu.2010.69 10.1111/j.1600-0609.2011.01618.x 10.1182/blood-2007-05-091850 10.1179/102453309X12473408860587 10.1182/blood-2009-05-224477 10.1016/j.leukres.2011.03.013 10.1038/nprot.2008.211 10.1097/00062752-199903000-00007 10.1016/j.exphem.2010.03.005 10.1182/blood-2010-04-279125 10.1056/NEJM199802263380902 10.1111/j.1365-2141.2007.06497.x |
ContentType | Journal Article |
Copyright | 2012 ISEH - Society for Hematology and Stem Cells ISEH - Society for Hematology and Stem Cells Copyright © 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2012 ISEH - Society for Hematology and Stem Cells – notice: ISEH - Society for Hematology and Stem Cells – notice: Copyright © 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.exphem.2012.05.011 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1873-2399 |
EndPage | 780.e19 |
ExternalDocumentID | 22659388 10_1016_j_exphem_2012_05_011 S0301472X12001865 1_s2_0_S0301472X12001865 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABGSF ABJNI ABMAC ABMZM ABUDA ABWVN ABXDB ACDAQ ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX ADVLN AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGRDE AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HX~ HZ~ IHE J1W K-O KOM L7B M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SCC SDF SDG SDH SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UDS X7M Y6R Z5R ZGI ZXP ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU DOVZS EFLBG LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c470t-b19f75f5ee0b7bf05a7a5f0f2167bbbfa60e0c849999c69cc2e66121454c53483 |
IEDL.DBID | .~1 |
ISSN | 0301-472X 1873-2399 |
IngestDate | Fri Jul 11 05:56:39 EDT 2025 Mon Jul 21 05:16:13 EDT 2025 Thu Apr 24 23:10:09 EDT 2025 Tue Jul 01 02:43:36 EDT 2025 Fri Feb 23 02:27:40 EST 2024 Sun Feb 23 10:19:44 EST 2025 Tue Aug 26 16:33:35 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
License | http://www.elsevier.com/open-access/userlicense/1.0 Copyright © 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c470t-b19f75f5ee0b7bf05a7a5f0f2167bbbfa60e0c849999c69cc2e66121454c53483 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.clinicalkey.com/#!/content/1-s2.0-S0301472X12001865 |
PMID | 22659388 |
PQID | 1033536846 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_1033536846 pubmed_primary_22659388 crossref_primary_10_1016_j_exphem_2012_05_011 crossref_citationtrail_10_1016_j_exphem_2012_05_011 elsevier_sciencedirect_doi_10_1016_j_exphem_2012_05_011 elsevier_clinicalkeyesjournals_1_s2_0_S0301472X12001865 elsevier_clinicalkey_doi_10_1016_j_exphem_2012_05_011 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-09-01 |
PublicationDateYYYYMMDD | 2012-09-01 |
PublicationDate_xml | – month: 09 year: 2012 text: 2012-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Experimental hematology |
PublicationTitleAlternate | Exp Hematol |
PublicationYear | 2012 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Huang da, Sherman, Lempicki (bib25) 2009; 4 Fernandez-Luna (bib28) 1999; 6 Berkofsky-Fessler, Buzzai, Kim (bib17) 2010; 16 Quintas-Cardama, Verstovsek (bib39) 2011; 20 Pettit, Lewis, Nicholas (bib27) 1979; 43 Jensen, de Nully, Lund, Nielsen, Hasselbalch (bib41) 2000; 110 Skov, Larsen, Thomassen, Riley (bib21) 2011; 87 Thiele, Kvasnicka (bib2) 2006; 47 Vardiman, Thiele, Arber (bib5) 2009; 114 Kiladjian, Mesa, Hoffman (bib34) 2011; 117 Tefferi (bib11) 2010; 24 Jensen, de Nully, Lund, Nielsen, Hasselbalch (bib42) 2001; 66 Kristinsson, Landgren, Samuelsson, Bjorkholm, Goldin (bib49) 2010; 95 Wilkins, Erber, Bareford (bib3) 2008; 111 Gnatenko, Zhu, Xu (bib22) 2010; 115 Srebrow, Kornblihtt (bib48) 2006; 119 Lu, Wang, Li (bib31) 2010; 116 Larsen, Pallisgaard, Moller, Hasselbalch (bib9) 2007; 79 Guglielmelli, Zini, Bogani (bib14) 2007; 25 Quintas-Cardama, Kantarjian, Manshouri (bib33) 2009; 27 Tefferi (bib37) 2005; 23 Barbui, Carobbio, Finazzi (bib45) 2011; 96 Skov, Larsen, Thomassen (bib20) 2012; 53 Venables (bib47) 2004; 64 Barbui, Thiele, Passamonti (bib4) 2011; 29 Lu, Zhang, Li (bib36) 2010; 38 Huang da, Sherman, Lempicki (bib26) 2009; 37 Desterke, Bilhou-Nabera, Guerton (bib38) 2011; 71 Puigdecanet, Espinet, Lozano (bib12) 2008; 22 Pellagatti, Vetrie, Langford (bib13) 2003; 63 Harrison, Cramer (bib43) 1993; 7 Kralovics, Teo, Buser (bib15) 2005; 106 Campbell, Green (bib10) 2006; 355 Catani, Zini, Sollazzo (bib18) 2009; 23 DAMESHEK (bib1) 1951; 6 Wernig, Mercher, Okabe, Levine, Lee, Gilliland (bib6) 2006; 107 Falanga, Marchetti, Vignoli (bib44) 2007; 35 Ghigna, Valacca, Biamonti (bib46) 2008; 9 Tiedt, Hao-Shen, Sobas (bib7) 2008; 111 Larsen, Moller, de Stricker (bib35) 2009; 14 Jones, Tefferi, Vuong, Desmond, Hofmann, Koeffler (bib16) 2005; 23 Li, Wong (bib24) 2001; 2 Will, Siddiqi, Jorda (bib30) 2010; 115 Kiladjian, Cassinat, Chevret (bib32) 2008; 112 Hasselbalch, Skov, Larsen (bib19) 2011 Oct; 35 Silva, Richard, Benito, Sanz, Olalla, Fernandez-Luna (bib29) 1998; 338 Larsen, Christensen, Hasselbalch, Pallisgaard (bib23) 2007; 136 Falanga, Marchetti, Vignoli, Balducci, Barbui (bib40) 2005; 33 Vannucchi, Pancrazzi, Bogani, Antonioli, Guglielmelli (bib8) 2006; 20 Plo, Nakatake, Malivert (bib50) 2008; 112 Wernig (10.1016/j.exphem.2012.05.011_bib6) 2006; 107 Larsen (10.1016/j.exphem.2012.05.011_bib9) 2007; 79 Jones (10.1016/j.exphem.2012.05.011_bib16) 2005; 23 Harrison (10.1016/j.exphem.2012.05.011_bib43) 1993; 7 Plo (10.1016/j.exphem.2012.05.011_bib50) 2008; 112 DAMESHEK (10.1016/j.exphem.2012.05.011_bib1) 1951; 6 Kristinsson (10.1016/j.exphem.2012.05.011_bib49) 2010; 95 Falanga (10.1016/j.exphem.2012.05.011_bib40) 2005; 33 Guglielmelli (10.1016/j.exphem.2012.05.011_bib14) 2007; 25 Skov (10.1016/j.exphem.2012.05.011_bib21) 2011; 87 Pellagatti (10.1016/j.exphem.2012.05.011_bib13) 2003; 63 Kralovics (10.1016/j.exphem.2012.05.011_bib15) 2005; 106 Jensen (10.1016/j.exphem.2012.05.011_bib41) 2000; 110 Venables (10.1016/j.exphem.2012.05.011_bib47) 2004; 64 Kiladjian (10.1016/j.exphem.2012.05.011_bib32) 2008; 112 Lu (10.1016/j.exphem.2012.05.011_bib36) 2010; 38 Barbui (10.1016/j.exphem.2012.05.011_bib4) 2011; 29 Quintas-Cardama (10.1016/j.exphem.2012.05.011_bib39) 2011; 20 Kiladjian (10.1016/j.exphem.2012.05.011_bib34) 2011; 117 Larsen (10.1016/j.exphem.2012.05.011_bib23) 2007; 136 Falanga (10.1016/j.exphem.2012.05.011_bib44) 2007; 35 Wilkins (10.1016/j.exphem.2012.05.011_bib3) 2008; 111 Jensen (10.1016/j.exphem.2012.05.011_bib42) 2001; 66 Ghigna (10.1016/j.exphem.2012.05.011_bib46) 2008; 9 Desterke (10.1016/j.exphem.2012.05.011_bib38) 2011; 71 Barbui (10.1016/j.exphem.2012.05.011_bib45) 2011; 96 Vannucchi (10.1016/j.exphem.2012.05.011_bib8) 2006; 20 Skov (10.1016/j.exphem.2012.05.011_bib20) 2012; 53 Hasselbalch (10.1016/j.exphem.2012.05.011_bib19) 2011; 35 Campbell (10.1016/j.exphem.2012.05.011_bib10) 2006; 355 Catani (10.1016/j.exphem.2012.05.011_bib18) 2009; 23 Tiedt (10.1016/j.exphem.2012.05.011_bib7) 2008; 111 Thiele (10.1016/j.exphem.2012.05.011_bib2) 2006; 47 Larsen (10.1016/j.exphem.2012.05.011_bib35) 2009; 14 Vardiman (10.1016/j.exphem.2012.05.011_bib5) 2009; 114 Srebrow (10.1016/j.exphem.2012.05.011_bib48) 2006; 119 Fernandez-Luna (10.1016/j.exphem.2012.05.011_bib28) 1999; 6 Lu (10.1016/j.exphem.2012.05.011_bib31) 2010; 116 Huang da (10.1016/j.exphem.2012.05.011_bib26) 2009; 37 Puigdecanet (10.1016/j.exphem.2012.05.011_bib12) 2008; 22 Berkofsky-Fessler (10.1016/j.exphem.2012.05.011_bib17) 2010; 16 Tefferi (10.1016/j.exphem.2012.05.011_bib37) 2005; 23 Li (10.1016/j.exphem.2012.05.011_bib24) 2001; 2 Tefferi (10.1016/j.exphem.2012.05.011_bib11) 2010; 24 Quintas-Cardama (10.1016/j.exphem.2012.05.011_bib33) 2009; 27 Silva (10.1016/j.exphem.2012.05.011_bib29) 1998; 338 Pettit (10.1016/j.exphem.2012.05.011_bib27) 1979; 43 Huang da (10.1016/j.exphem.2012.05.011_bib25) 2009; 4 Gnatenko (10.1016/j.exphem.2012.05.011_bib22) 2010; 115 Will (10.1016/j.exphem.2012.05.011_bib30) 2010; 115 |
References_xml | – volume: 24 start-page: 1128 year: 2010 end-page: 1138 ident: bib11 article-title: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 publication-title: Leukemia – volume: 79 start-page: 508 year: 2007 end-page: 515 ident: bib9 article-title: The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis—impact on disease phenotype publication-title: Eur J Haematol – volume: 7 start-page: 52 year: 1993 end-page: 62 ident: bib43 article-title: Platelet alpha-granules publication-title: Blood Rev – volume: 64 start-page: 7647 year: 2004 end-page: 7654 ident: bib47 article-title: Aberrant and alternative splicing in cancer publication-title: Cancer Res – volume: 115 start-page: 2901 year: 2010 end-page: 2909 ident: bib30 article-title: Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells publication-title: Blood – volume: 22 start-page: 1368 year: 2008 end-page: 1376 ident: bib12 article-title: Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia publication-title: Leukemia – volume: 71 start-page: 2901 year: 2011 end-page: 2915 ident: bib38 article-title: FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis publication-title: Cancer Res – volume: 96 start-page: 315 year: 2011 end-page: 318 ident: bib45 article-title: Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 publication-title: Haematologica – volume: 6 start-page: 372 year: 1951 end-page: 375 ident: bib1 article-title: Some speculations on the myeloproliferative syndromes publication-title: Blood – volume: 23 start-page: 997 year: 2009 end-page: 1000 ident: bib18 article-title: Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia publication-title: Leukemia – volume: 23 start-page: 8520 year: 2005 end-page: 8530 ident: bib37 article-title: Pathogenesis of myelofibrosis with myeloid metaplasia publication-title: J Clin Oncol – volume: 119 start-page: 2635 year: 2006 end-page: 2641 ident: bib48 article-title: The connection between splicing and cancer publication-title: J Cell Sci – volume: 136 start-page: 745 year: 2007 end-page: 751 ident: bib23 article-title: The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders publication-title: Br J Haematol – volume: 338 start-page: 564 year: 1998 end-page: 571 ident: bib29 article-title: Expression of Bcl-x in erythroid precursors from patients with polycythemia vera publication-title: N Engl J Med – volume: 110 start-page: 116 year: 2000 end-page: 124 ident: bib41 article-title: Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders publication-title: Br J Haematol – volume: 111 start-page: 60 year: 2008 end-page: 70 ident: bib3 article-title: Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes publication-title: Blood – volume: 111 start-page: 3931 year: 2008 end-page: 3940 ident: bib7 article-title: Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice publication-title: Blood – volume: 38 start-page: 472 year: 2010 end-page: 480 ident: bib36 article-title: Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway publication-title: Exp Hematol – volume: 23 start-page: 631 year: 2005 end-page: 637 ident: bib16 article-title: Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays publication-title: Stem Cells – volume: 16 start-page: 4339 year: 2010 end-page: 4352 ident: bib17 article-title: Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F publication-title: Clin Cancer Res – volume: 106 start-page: 3374 year: 2005 end-page: 3376 ident: bib15 article-title: Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 publication-title: Blood – volume: 95 start-page: 1216 year: 2010 end-page: 1220 ident: bib49 article-title: Autoimmunity and the risk of myeloproliferative neoplasms publication-title: Haematologica – volume: 63 start-page: 3940 year: 2003 end-page: 3944 ident: bib13 article-title: Gene expression profiling in polycythemia vera using cDNA microarray technology publication-title: Cancer Res – volume: 112 start-page: 3065 year: 2008 end-page: 3072 ident: bib32 article-title: Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera publication-title: Blood – volume: 37 start-page: 1 year: 2009 end-page: 13 ident: bib26 article-title: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists publication-title: Nucleic Acids Res – volume: 20 start-page: 961 year: 2011 end-page: 972 ident: bib39 article-title: New JAK2 inhibitors for myeloproliferative neoplasms publication-title: Expert Opin Investig Drugs – volume: 35 start-page: 1330 year: 2011 Oct end-page: 1334 ident: bib19 article-title: High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis publication-title: Leuk Res – volume: 116 start-page: 4284 year: 2010 end-page: 4287 ident: bib31 article-title: Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon alpha specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells publication-title: Blood – volume: 43 start-page: 167 year: 1979 end-page: 184 ident: bib27 article-title: Transitional myeloproliferative disorder publication-title: Br J Haematol – volume: 6 start-page: 94 year: 1999 end-page: 99 ident: bib28 article-title: Apoptosis and polycythemia vera publication-title: Curr Opin Hematol – volume: 27 start-page: 5418 year: 2009 end-page: 5424 ident: bib33 article-title: Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera publication-title: J Clin Oncol – volume: 2 start-page: 1 year: 2001 end-page: 11 ident: bib24 article-title: Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application publication-title: Genome Biol – volume: 20 start-page: 1055 year: 2006 end-page: 1060 ident: bib8 article-title: A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis publication-title: Leukemia – volume: 35 start-page: 702 year: 2007 end-page: 711 ident: bib44 article-title: V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules publication-title: Exp Hematol – volume: 47 start-page: 381 year: 2006 end-page: 396 ident: bib2 article-title: A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders publication-title: Leuk Lymphoma – volume: 115 start-page: 7 year: 2010 end-page: 14 ident: bib22 article-title: Class prediction models of thrombocytosis using genetic biomarkers publication-title: Blood – volume: 114 start-page: 937 year: 2009 end-page: 951 ident: bib5 article-title: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes publication-title: Blood – volume: 355 start-page: 2452 year: 2006 end-page: 2466 ident: bib10 article-title: The myeloproliferative disorders publication-title: N Engl J Med – volume: 25 start-page: 165 year: 2007 end-page: 173 ident: bib14 article-title: Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1) publication-title: Stem Cells – volume: 14 start-page: 331 year: 2009 end-page: 334 ident: bib35 article-title: Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission publication-title: Hematology – volume: 87 start-page: 54 year: 2011 end-page: 60 ident: bib21 article-title: Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis publication-title: Eur J Haematol – volume: 9 start-page: 556 year: 2008 end-page: 570 ident: bib46 article-title: Alternative splicing and tumor progression publication-title: Curr Genomics – volume: 107 start-page: 4274 year: 2006 end-page: 4281 ident: bib6 article-title: Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model publication-title: Blood – volume: 66 start-page: 143 year: 2001 end-page: 151 ident: bib42 article-title: Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count publication-title: Eur J Haematol – volume: 53 start-page: 123 year: 2012 end-page: 129 ident: bib20 article-title: Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms publication-title: Leuk Lymphoma – volume: 29 start-page: 3179 year: 2011 end-page: 3184 ident: bib4 article-title: Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study publication-title: J Clin Oncol – volume: 4 start-page: 44 year: 2009 end-page: 57 ident: bib25 article-title: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources publication-title: Nat Protoc – volume: 112 start-page: 1402 year: 2008 end-page: 1412 ident: bib50 article-title: JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders publication-title: Blood – volume: 117 start-page: 4706 year: 2011 end-page: 4715 ident: bib34 article-title: The renaissance of interferon therapy for the treatment of myeloid malignancies publication-title: Blood – volume: 33 start-page: 523 year: 2005 end-page: 530 ident: bib40 article-title: Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera publication-title: Exp Hematol – volume: 47 start-page: 381 year: 2006 ident: 10.1016/j.exphem.2012.05.011_bib2 article-title: A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders publication-title: Leuk Lymphoma doi: 10.1080/10428190500331329 – volume: 27 start-page: 5418 year: 2009 ident: 10.1016/j.exphem.2012.05.011_bib33 article-title: Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.6075 – volume: 64 start-page: 7647 year: 2004 ident: 10.1016/j.exphem.2012.05.011_bib47 article-title: Aberrant and alternative splicing in cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-1910 – volume: 63 start-page: 3940 year: 2003 ident: 10.1016/j.exphem.2012.05.011_bib13 article-title: Gene expression profiling in polycythemia vera using cDNA microarray technology publication-title: Cancer Res – volume: 112 start-page: 1402 year: 2008 ident: 10.1016/j.exphem.2012.05.011_bib50 article-title: JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders publication-title: Blood doi: 10.1182/blood-2008-01-134114 – volume: 37 start-page: 1 year: 2009 ident: 10.1016/j.exphem.2012.05.011_bib26 article-title: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists publication-title: Nucleic Acids Res doi: 10.1093/nar/gkn923 – volume: 112 start-page: 3065 year: 2008 ident: 10.1016/j.exphem.2012.05.011_bib32 article-title: Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera publication-title: Blood doi: 10.1182/blood-2008-03-143537 – volume: 33 start-page: 523 year: 2005 ident: 10.1016/j.exphem.2012.05.011_bib40 article-title: Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera publication-title: Exp Hematol doi: 10.1016/j.exphem.2005.01.015 – volume: 96 start-page: 315 year: 2011 ident: 10.1016/j.exphem.2012.05.011_bib45 article-title: Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 publication-title: Haematologica doi: 10.3324/haematol.2010.031070 – volume: 35 start-page: 702 year: 2007 ident: 10.1016/j.exphem.2012.05.011_bib44 article-title: V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules publication-title: Exp Hematol doi: 10.1016/j.exphem.2007.01.053 – volume: 95 start-page: 1216 year: 2010 ident: 10.1016/j.exphem.2012.05.011_bib49 article-title: Autoimmunity and the risk of myeloproliferative neoplasms publication-title: Haematologica doi: 10.3324/haematol.2009.020412 – volume: 79 start-page: 508 year: 2007 ident: 10.1016/j.exphem.2012.05.011_bib9 article-title: The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis—impact on disease phenotype publication-title: Eur J Haematol doi: 10.1111/j.1600-0609.2007.00960.x – volume: 355 start-page: 2452 year: 2006 ident: 10.1016/j.exphem.2012.05.011_bib10 article-title: The myeloproliferative disorders publication-title: N Engl J Med doi: 10.1056/NEJMra063728 – volume: 2 start-page: 1 year: 2001 ident: 10.1016/j.exphem.2012.05.011_bib24 article-title: Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application publication-title: Genome Biol doi: 10.1186/gb-2001-2-8-research0032 – volume: 106 start-page: 3374 year: 2005 ident: 10.1016/j.exphem.2012.05.011_bib15 article-title: Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 publication-title: Blood doi: 10.1182/blood-2005-05-1889 – volume: 119 start-page: 2635 year: 2006 ident: 10.1016/j.exphem.2012.05.011_bib48 article-title: The connection between splicing and cancer publication-title: J Cell Sci doi: 10.1242/jcs.03053 – volume: 6 start-page: 372 year: 1951 ident: 10.1016/j.exphem.2012.05.011_bib1 article-title: Some speculations on the myeloproliferative syndromes publication-title: Blood doi: 10.1182/blood.V6.4.372.372 – volume: 66 start-page: 143 year: 2001 ident: 10.1016/j.exphem.2012.05.011_bib42 article-title: Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count publication-title: Eur J Haematol doi: 10.1034/j.1600-0609.2001.00359.x – volume: 110 start-page: 116 year: 2000 ident: 10.1016/j.exphem.2012.05.011_bib41 article-title: Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2000.02030.x – volume: 117 start-page: 4706 year: 2011 ident: 10.1016/j.exphem.2012.05.011_bib34 article-title: The renaissance of interferon therapy for the treatment of myeloid malignancies publication-title: Blood doi: 10.1182/blood-2010-08-258772 – volume: 9 start-page: 556 year: 2008 ident: 10.1016/j.exphem.2012.05.011_bib46 article-title: Alternative splicing and tumor progression publication-title: Curr Genomics doi: 10.2174/138920208786847971 – volume: 115 start-page: 2901 year: 2010 ident: 10.1016/j.exphem.2012.05.011_bib30 article-title: Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells publication-title: Blood doi: 10.1182/blood-2009-03-209544 – volume: 71 start-page: 2901 year: 2011 ident: 10.1016/j.exphem.2012.05.011_bib38 article-title: FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-1731 – volume: 29 start-page: 3179 year: 2011 ident: 10.1016/j.exphem.2012.05.011_bib4 article-title: Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study publication-title: J Clin Oncol doi: 10.1200/JCO.2010.34.5298 – volume: 114 start-page: 937 year: 2009 ident: 10.1016/j.exphem.2012.05.011_bib5 article-title: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes publication-title: Blood doi: 10.1182/blood-2009-03-209262 – volume: 20 start-page: 1055 year: 2006 ident: 10.1016/j.exphem.2012.05.011_bib8 article-title: A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis publication-title: Leukemia doi: 10.1038/sj.leu.2404209 – volume: 23 start-page: 8520 year: 2005 ident: 10.1016/j.exphem.2012.05.011_bib37 article-title: Pathogenesis of myelofibrosis with myeloid metaplasia publication-title: J Clin Oncol doi: 10.1200/JCO.2004.00.9316 – volume: 16 start-page: 4339 year: 2010 ident: 10.1016/j.exphem.2012.05.011_bib17 article-title: Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-1092 – volume: 25 start-page: 165 year: 2007 ident: 10.1016/j.exphem.2012.05.011_bib14 article-title: Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1) publication-title: Stem Cells doi: 10.1634/stemcells.2006-0351 – volume: 7 start-page: 52 year: 1993 ident: 10.1016/j.exphem.2012.05.011_bib43 article-title: Platelet alpha-granules publication-title: Blood Rev doi: 10.1016/0268-960X(93)90024-X – volume: 107 start-page: 4274 year: 2006 ident: 10.1016/j.exphem.2012.05.011_bib6 article-title: Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model publication-title: Blood doi: 10.1182/blood-2005-12-4824 – volume: 111 start-page: 3931 year: 2008 ident: 10.1016/j.exphem.2012.05.011_bib7 article-title: Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice publication-title: Blood doi: 10.1182/blood-2007-08-107748 – volume: 23 start-page: 997 year: 2009 ident: 10.1016/j.exphem.2012.05.011_bib18 article-title: Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia publication-title: Leukemia doi: 10.1038/leu.2008.357 – volume: 20 start-page: 961 year: 2011 ident: 10.1016/j.exphem.2012.05.011_bib39 article-title: New JAK2 inhibitors for myeloproliferative neoplasms publication-title: Expert Opin Investig Drugs doi: 10.1517/13543784.2011.579560 – volume: 43 start-page: 167 year: 1979 ident: 10.1016/j.exphem.2012.05.011_bib27 article-title: Transitional myeloproliferative disorder publication-title: Br J Haematol doi: 10.1111/j.1365-2141.1979.tb03739.x – volume: 22 start-page: 1368 year: 2008 ident: 10.1016/j.exphem.2012.05.011_bib12 article-title: Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia publication-title: Leukemia doi: 10.1038/leu.2008.112 – volume: 53 start-page: 123 year: 2012 ident: 10.1016/j.exphem.2012.05.011_bib20 article-title: Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms publication-title: Leuk Lymphoma doi: 10.3109/10428194.2011.597905 – volume: 23 start-page: 631 year: 2005 ident: 10.1016/j.exphem.2012.05.011_bib16 article-title: Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays publication-title: Stem Cells doi: 10.1634/stemcells.2004-0131 – volume: 24 start-page: 1128 year: 2010 ident: 10.1016/j.exphem.2012.05.011_bib11 article-title: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 publication-title: Leukemia doi: 10.1038/leu.2010.69 – volume: 87 start-page: 54 year: 2011 ident: 10.1016/j.exphem.2012.05.011_bib21 article-title: Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis publication-title: Eur J Haematol doi: 10.1111/j.1600-0609.2011.01618.x – volume: 111 start-page: 60 year: 2008 ident: 10.1016/j.exphem.2012.05.011_bib3 article-title: Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes publication-title: Blood doi: 10.1182/blood-2007-05-091850 – volume: 14 start-page: 331 year: 2009 ident: 10.1016/j.exphem.2012.05.011_bib35 article-title: Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission publication-title: Hematology doi: 10.1179/102453309X12473408860587 – volume: 115 start-page: 7 year: 2010 ident: 10.1016/j.exphem.2012.05.011_bib22 article-title: Class prediction models of thrombocytosis using genetic biomarkers publication-title: Blood doi: 10.1182/blood-2009-05-224477 – volume: 35 start-page: 1330 issue: 10 year: 2011 ident: 10.1016/j.exphem.2012.05.011_bib19 article-title: High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis publication-title: Leuk Res doi: 10.1016/j.leukres.2011.03.013 – volume: 4 start-page: 44 year: 2009 ident: 10.1016/j.exphem.2012.05.011_bib25 article-title: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources publication-title: Nat Protoc doi: 10.1038/nprot.2008.211 – volume: 6 start-page: 94 year: 1999 ident: 10.1016/j.exphem.2012.05.011_bib28 article-title: Apoptosis and polycythemia vera publication-title: Curr Opin Hematol doi: 10.1097/00062752-199903000-00007 – volume: 38 start-page: 472 year: 2010 ident: 10.1016/j.exphem.2012.05.011_bib36 article-title: Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway publication-title: Exp Hematol doi: 10.1016/j.exphem.2010.03.005 – volume: 116 start-page: 4284 year: 2010 ident: 10.1016/j.exphem.2012.05.011_bib31 article-title: Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon alpha specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells publication-title: Blood doi: 10.1182/blood-2010-04-279125 – volume: 338 start-page: 564 year: 1998 ident: 10.1016/j.exphem.2012.05.011_bib29 article-title: Expression of Bcl-x in erythroid precursors from patients with polycythemia vera publication-title: N Engl J Med doi: 10.1056/NEJM199802263380902 – volume: 136 start-page: 745 year: 2007 ident: 10.1016/j.exphem.2012.05.011_bib23 article-title: The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2007.06497.x |
SSID | ssj0005590 |
Score | 2.2724085 |
Snippet | The recent discovery of the Janus activating kinase 2 V617F mutation in most patients with polycythemia vera (PV) and half of those with essential... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 771 |
SubjectTerms | Adult Advanced Basic Science Aged Aged, 80 and over Cluster Analysis Female Gene Expression Profiling - statistics & numerical data Hematology, Oncology, and Palliative Medicine Humans Janus Kinase 2 - genetics Male Middle Aged Oligonucleotide Array Sequence Analysis - statistics & numerical data Polycythemia Vera - genetics Polycythemia Vera - pathology Primary Myelofibrosis - genetics Primary Myelofibrosis - pathology Principal Component Analysis Thrombocythemia, Essential - genetics Thrombocythemia, Essential - pathology |
Title | Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0301472X12001865 https://www.clinicalkey.es/playcontent/1-s2.0-S0301472X12001865 https://dx.doi.org/10.1016/j.exphem.2012.05.011 https://www.ncbi.nlm.nih.gov/pubmed/22659388 https://www.proquest.com/docview/1033536846 |
Volume | 40 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_HCeKL-O16ekTwtW7bJE37eCwe68cdoh7sW0jSBCu7bbFduH3xn_EfdaZplxM9TnwqTZOm6UwyvyS_mRDySpa81IAcorL0PuIAWaNCSxnxLE-043lZDtsFZ-fZ8oK_W4nVAVlMvjBIqxzH_jCmD6P1mDIf_-a8rar552E2INNVgrSgPENHc84lavnrH1doHiKss0DmCHNP7nMDx8tdtl8d-qPjiiDG70yuM0_Xwc_BDJ3eI3dH_EhPwifeJweufkBun4075A_JT4wjTaHGwG-taTiUGwwUxSVX2obFdXgFksmbGmwO1WNgElq6trJ9RwEU0hCdCUVIkc5e1dvthqIzCsVo45AAD_CMhY1p7A5Dv1aaIh2Uts16t0-BBE37hm52bg3fYaDRVfeIXJy--bJYRuNBDJHlMu4jkxReCi-ci400PhZaauFjnyaZNMZ4ncUutjlOngqbFdamLsPIZFxwKxjP2WNyWEOLnhKqjZelS5xzGUzKfZrbAjCeTHTKtGAFmxE2_X9lxyjleFjGWk10tG8qSE2h1FQsFEhtRqJ9qTZE6bghv5hEqyYPVBgzFZiRG8rJv5Vz3djxO5WoDjKrP5Tzasnf9Psf6nw56Z6Cro_7Obp2zRbqihkTLAMEOSNPglLuWw-oWhQsz5_9d71H5A7eBT7dc3LYf9-6FwDAenM89LBjcutk8enDR7y-fb88_wV10zbD |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9wgEEbpRmp7qfru9kmlXq31C2Mfo6jRpsnupYm0NwQYVEe7tlV7pezvyR_tjMHbVm2UqldgjGGAGeCbD0I-8TItJXgOQVlaG6TgsgaF5DxIszySJs3LcrguWCyz-WX6ZcVWB-R4jIVBWKVf-92aPqzWPmXme3PWVtXs67Ab4PEqQlhQnrF75BDZqdiEHB6dns2XP5EezB21QPkABcYIugHmZa7bbwZD0vFQECk8o9ss1G0e6GCJTh6TR96FpEfuL5-QA1M_JfcX_pL8GblBKmkKNTqIa03du9xgoyieutLWna_DJxBP3tRgdqj03CS0NG2l-46CX0gdQRNqkSKivaq32w3FeBSKhOOQABn4zMJGNXqH7K-VpIgIpW2z3u1TIEHSvqGbnVnDfyhodNU9J5cnny-O54F_iyHQKQ_7QEWF5cwyY0LFlQ2Z5JLZ0MZRxpVSVmahCXWO-6dCZ4XWscmQnAw0olmS5skLMqmhRa8Ilcry0kTGmAz25TbOdQFuHo9knEiWFMmUJGP_C-2JyvG9jLUYEWlXwmlNoNZEyARobUqCvVTriDruKM9G1YoxCBWWTQGW5A45_jc50_m534lIdFBY_DE-f5X8bYj_Q50fx7EnYPbjlY6sTbOFusIkYUkGTuSUvHSDct96cKxZkeT56_-u9wN5ML9YnIvz0-XZG_IQcxy87i2Z9N-35h34Y7167-fbDzVIN98 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gene+expression+profiling+with+principal+component+analysis+depicts+the+biological+continuum+from+essential+thrombocythemia+over+polycythemia+vera+to+myelofibrosis&rft.jtitle=Experimental+hematology&rft.au=Skov%2C+Vibe&rft.au=Thomassen%2C+Mads&rft.au=Riley%2C+Caroline+H&rft.au=Jensen%2C+Morten+K&rft.date=2012-09-01&rft.issn=0301-472X&rft.volume=40&rft.issue=9&rft.spage=771&rft.epage=780.e19&rft_id=info:doi/10.1016%2Fj.exphem.2012.05.011&rft.externalDBID=ECK1-s2.0-S0301472X12001865&rft.externalDocID=1_s2_0_S0301472X12001865 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0301472X%2FS0301472X11X00218%2Fcov150h.gif |